RxDoctor Payments Data

Sara Valente, MD

Urology · Rockport, MENPI 1912310723

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Teleflex LLC at 29.0% of the total.

$2,730in general payments, 2019–2025

Across 43 payments — averaging $63.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$793
  • Cook Medical LLC$383
  • AbbVie$287
  • Innovation Technologies Inc$221
  • Astellas Pharma US Inc$220
  • Axonics, Inc.$156
  • plus $670 from 12 others

What the payments were for

  • Travel & lodging$1,08140%
  • Food & beverage$1,36150%
  • Education$28811%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,730 in reported general payments places this provider in the 75th percentile of 59 urology providers in Maine.

See all urology providers in Maine

Medicare billing

Part B allowed, 2024
$40,780
Medicare patients
272
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron135$80,951
GemtesaVibegron33$15,407
Tamsulosin Hcl384$4,673
Mirabegron ErMirabegron11$3,916
Finasteride270$3,208
Tolterodine Tartrate ErTolterodine Tartrate18$2,888
Oxybutynin Chloride ErOxybutynin Chloride171$2,707
Estradiol33$1,894
Solifenacin Succinate15$1,812
Alfuzosin Hcl ErAlfuzosin Hcl91$1,767
Trospium Chloride ErTrospium Chloride12$1,736
Cephalexin69$362
Oxybutynin Chloride28$310
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$190
Ciprofloxacin Hcl16$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$220$80,951135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 59 urology providers in Maine.

Other urology in Rockport

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →